Kasvu Raises €30M for Depression Drug Targeting TrkB - European Biotechnology Magazine

Kasvu Therapeutics Raises €30 Million to Advance Novel TrkB-Targeting Depression Drug Candidate KTX-0141 Toward Human Trials

Kasvu Therapeutics Raises €30 Million to Advance Novel TrkB-Targeting Depression Drug Candidate KTX-0141 Toward Human Trials (IN BRIEF) Kasvu Therapeutics, a University of Helsinki spinout, has raised €30 million to advance KTX-0141, a preclinical drug candidate for major depressive disorder, toward first-in-human studies that could begin as early as summer 2027. The financing, led by Hadean Ventures with participation from Tesi, Innovestor Life…

Kasvu raises €30M for depression drug targeting TrkB - European Biotechnology Magazine

Finnish biotech Kasvu Therapeutics has raised €30 million in Series A financing to take its lead depression candidate into clinical development, adding to a growing number of European investments in drugs targeting TrkB, a receptor involved in the brain’s ability to form and adapt neural connections.

Kasvu Therapeutics Raises €30 Million Series A Financing Round led by Hadean Ventures to Advance its Novel TrkB Potentiator into Clinical Development Targeting Neuropsychiatric Disorders

Kasvu Therapeutics From Left to Right: Matti Karvonen, CMO; Jami Mandelin, CEO and Co-founder and Georgios Trichas, CBO Differentiated approach directly and selectively enhances TrkB activity, a central regulator of neuroplasticity New funds will advance lead programme KTX-0141 through IND/CTA-enabling studies and Phase 1/1b clinical development targeting major depressive disorder Financing round was led by [...]